Pharmaceuticals firm says third dose of its Covid vaccine increases antibodies against variant by 37-fold
The pharmaceuticals company Moderna has said a booster dose of its Covid vaccine appeared to protect against the fast-spreading Omicron variant in laboratory testing and that the current version will continue to beits “first line of defence against Omicron”.
The decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the variant is spreading. The company plans to develop a vaccine specifically to protect against Omicron, which it hopes to advance into clinical trials early next year.
